GRAIL (GRAL) Projected to Post Quarterly Earnings on Thursday

GRAIL (NASDAQ:GRAL) is expected to be releasing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect GRAIL to post earnings of ($3.33) per share and revenue of $43.3330 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 5:00 PM ET.

GRAIL Trading Up 1.6%

Shares of NASDAQ:GRAL opened at $99.03 on Wednesday. GRAIL has a 52 week low of $20.44 and a 52 week high of $118.84. The company’s 50 day moving average is $97.15 and its two-hundred day moving average is $75.45. The company has a market cap of $3.86 billion, a PE ratio of -8.52 and a beta of 4.52.

Institutional Trading of GRAIL

Several institutional investors and hedge funds have recently bought and sold shares of GRAL. Farallon Capital Management LLC boosted its stake in GRAIL by 73.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock worth $200,510,000 after purchasing an additional 993,684 shares during the period. State Street Corp boosted its stake in shares of GRAIL by 38.8% during the fourth quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after buying an additional 510,546 shares during the period. Morgan Stanley grew its holdings in shares of GRAIL by 63.8% during the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock worth $129,385,000 after buying an additional 588,647 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in GRAIL in the 4th quarter valued at about $37,874,000. Finally, RA Capital Management L.P. purchased a new stake in GRAIL during the 4th quarter valued at approximately $36,655,000.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Canaccord Genuity Group raised their price target on GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Robert W. Baird started coverage on GRAIL in a report on Tuesday. They issued an “outperform” rating and a $113.00 price objective on the stock. Guggenheim boosted their target price on GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Finally, Morgan Stanley raised their price objective on shares of GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $106.60.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.